Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major

Haematologica

Volumn 96, Issue 2, 2011, Pages

  Musallam, Khaled M ^a   Taher, Ali T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Deferasirox; Deferiprone; Heart; Iron overload; Mri

Indexed keywords

DEFERASIROX; DEFERIPRONE; FERRITIN; IRON;

BETA THALASSEMIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FERRITIN BLOOD LEVEL; HEART HEMOSIDEROSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON BALANCE; IRON LIVER LEVEL; IRON METABOLISM; LETTER; LIVER LEVEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; THALASSEMIA MAJOR; TREATMENT DURATION;

BETA-THALASSEMIA; HEART DISEASES; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; PYRIDONES; SIDEROSIS;

EID: 79551635969     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.036061     Document Type: Letter

References (10)

1. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, et al.Deferasirox, Deferiprone and Desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative Magnetic Resonance Imaging. Haematologica. 2010; DOI: 10.3324/haematol.2009.019042.
2. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-44.
3. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360(9332):516-20.
4. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115(12):2364-71.
5. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537-43.
6. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009;42(3):247-51.
7. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-7.
8. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348-55.
9. Pennell D, Porter J, Cappellini M, Chan LL, El-Beshlawy A, Aydinok Y, et al. Continued improvement in cardiac t2* with deferasirox treatment over 2 years: results from the extension of EPIC cardiac substudy in beta-thalassaemia patients with myocardial siderosis. Haematologica. 2010;95(Suppl 2):202, abs 0498.
10. Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev. 2008;22(Suppl 2):S14-21.